Post by PharmaShots

Guardant Health gains FDA approval for Guardant360 CDx as a blood-based companion diagnostic for Veppanu (vepdegestrant), enabling identification of ESR1-mutated advanced breast cancer patients eligible for targeted therapy and advancing precision oncology adoption Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #guardanthealth #usfda #approval #guardant360cdx #companiondiagnostic #arvinas #veppanu #medtech https://lnkd.in/gbZuHfPe